Rezafungin acetate
(Synonyms: Biafungin acetate; CD101 acetate; SP-3025 acetate) 目录号 : GC60321Rezafungin (Biafungin) 是下一代,广谱且持久的棘皮菌素。Rezafungin acetate 显示对念珠菌,曲霉和肺孢子菌具有有效的抗真菌活性。
Cas No.:1631754-41-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Rezafungin acetate (Biafungin acetate) is a next-generation, broad-spectrum, and long-lasting echinocandin. Rezafungin acetate shows potent antifungal activity against Candida spp., Aspergillus spp., and Pneumocystis spp.[1][2].
Rezafungin acetate (Biafungin acetate) (1 mg/kg; i.p. once daily for 6 days) shows potent in vivo efficacy as prophylaxis against Pneumocystis in an in vivo mouse infection model[1]. Animal Model: C3H/HeN mice[1]
[1]. Melanie Cushion, et al. Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia. VOLUME 25, ISSUE 3, SUPPLEMENT, S366, MARCH 01, 2019. [2]. Sofjan AK, et al. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 Sep;14:58-64.
Cas No. | 1631754-41-0 | SDF | |
别名 | Biafungin acetate; CD101 acetate; SP-3025 acetate | ||
Canonical SMILES | O=C1N2[C@]([C@@H](O)[C@@H](C)C2)([H])C(N[C@]([C@@H](C[C@@H](C(N[C@]([C@H](O)C)([H])C(N3[C@](C[C@@H](O)C3)([H])C(N[C@]([C@H](O)[C@H](C4=CC=C(O)C=C4)O)([H])C(N[C@@]1([H])[C@H](O)C)=O)=O)=O)=O)NC(C5=CC=C(C6=CC=C(C7=CC=C(OCCCCC)C=C7)C=C6)C=C5)=O)O)([H])OCC[N+](C)(C)C)=O.[O-]C(C)=O | ||
分子式 | C65H88N8O19 | 分子量 | 1285.44 |
溶解度 | DMSO : 230 mg/mL (178.93 mM; Need ultrasonic) | 储存条件 | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.7779 mL | 3.8897 mL | 7.7794 mL |
5 mM | 0.1556 mL | 0.7779 mL | 1.5559 mL |
10 mM | 0.0778 mL | 0.389 mL | 0.7779 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
Pharmacol Res Perspect 2019 Nov 20;7(6):e00546.PMID:31763045DOI:PMC6864408
Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half-life allowing once-weekly administration, front-loaded plasma drug exposures associated with antifungal efficacy, and penetration into deep-seated infections, such as intra-abdominal abscesses. In this series of in vivo studies, rezafungin demonstrated efficacy in the treatment of neutropenic mouse models of disseminated candidiasis, including infection caused by azole-resistant Candida albicans, and aspergillosis. These results contribute to a growing body of evidence demonstrating the antifungal efficacy and potential utility of rezafungin in the treatment of invasive fungal infections.